In the CCl4-induced FAT-NASH mouse model, FASN inhibition decreased hepatic fibrosis and fibrosis markers, and development of hepatocellular carcinoma (HCC) tumors by 85%. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatohepatitis.